Alpha-2B Adrenergic Receptor Agonists for Regulatory T Cell Upregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving T cell dysfunction, such as neuritis, Guillain-Barre syndrome, and multiple sclerosis, lack effective methods to modulate T cell activity, leading to inadequate therapeutic outcomes.
Innovation Solution
Administering alpha-2B receptor agonists, specifically compounds with significant efficacy at alpha-2B adrenergic receptors and minimal activity at alpha-2A receptors, to upregulate regulatory T cell function and treat various autoimmune and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional T cell treatments are used, then disease symptoms may be managed, but T cell activity cannot be effectively modulated
Solution Approach 1:
The patent changes the pharmacological parameter by selectively targeting alpha-2B adrenergic receptors with high affinity and specificity. The compounds described have IC50 values in the nanomolar range (e.g., 0.1-10 nM) at alpha-2B receptors while showing minimal activity at alpha-2A and alpha-2C receptors, creating a novel therapeutic parameter space that enables effective T cell modulation without previous treatment limitations
Solution Approach 2:
The patent introduces alpha-2B adrenergic receptors as an intermediary target between the administered compounds and T cell function modulation. By binding to this specific receptor subtype on regulatory T cells, the compounds mediate their therapeutic effect through receptor activation, which then translates into enhanced T cell activity and improved disease outcomes
2Adaptability or versatility
If alpha-2A receptor agonists are used, then general adrenergic activity is achieved, but selective T cell modulation is insufficient
Solution Approach 1:
The patent segments the adrenergic receptor system by focusing exclusively on alpha-2B receptor activity while minimizing activity at other alpha-2 subtypes. This segmentation allows for selective modulation of T cell function through alpha-2B receptor activation alone, avoiding the non-specific effects of pan-adrenergic agents and achieving more precise therapeutic control
Solution Approach 2:
The patent applies local quality by creating compounds with differentiated receptor binding characteristics. The molecular structures are designed to exhibit high affinity for alpha-2B receptors (IC50 < 10 nM) while showing minimal binding to alpha-2A and alpha-2C receptors, thereby concentrating the pharmacological effect at the specific target site where it is most needed for T cell modulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The alpha-2B receptor agonists effectively increase regulatory T cell frequency and reduce immune cell infiltration, providing sustained therapeutic benefits for diseases like multiple sclerosis and autoimmune uveitis, with compounds like Compound B and Compound C demonstrating significant clinical effects in animal models.
Implementation Method 1
there are alpha-2B adrenergic receptors on a subtype of T cells, and that alpha-2 receptor agonists may be used to modulate the activity of such T cells
Implementation Method 2
alpha-2B adrenergic receptor agonists... increase regulatory T cell function
Data Source
AI summary
Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.